scispace - formally typeset
Open AccessJournal ArticleDOI

Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010

Reads0
Chats0
TLDR
Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time.
Abstract
Importance Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them. Objective To determine the association between the presence of state medical cannabis laws and opioid analgesic overdose mortality. Design, Setting, and Participants A time-series analysis was conducted of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010; all 50 states were included. Exposures Presence of a law establishing a medical cannabis program in the state. Main Outcomes and Measures Age-adjusted opioid analgesic overdose death rate per 100 000 population in each state. Regression models were developed including state and year fixed effects, the presence of 3 different policies regarding opioid analgesics, and the state-specific unemployment rate. Results Three states (California, Oregon, and Washington) had medical cannabis laws effective prior to 1999. Ten states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) enacted medical cannabis laws between 1999 and 2010. States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate (95% CI, −37.5% to −9.5%; P  = .003) compared with states without medical cannabis laws. Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time: year 1 (−19.9%; 95% CI, −30.6% to −7.7%; P  = .002), year 2 (−25.2%; 95% CI, −40.6% to −5.9%; P  = .01), year 3 (−23.6%; 95% CI, −41.1% to −1.0%; P  = .04), year 4 (−20.2%; 95% CI, −33.6% to −4.0%; P  = .02), year 5 (−33.7%; 95% CI, −50.9% to −10.4%; P  = .008), and year 6 (−33.3%; 95% CI, −44.7% to −19.6%; P Conclusions and Relevance Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.

read more

Citations
More filters
Journal ArticleDOI

The Effects of Recreational Marijuana Legalization on Employment and Earnings

TL;DR: This paper explored the impacts of recreational marijuana laws (RMLs) on employment and wages and found that RML adoption is associated with an increase in agricultural employment, consistent with the opening of a new licit market.
Journal ArticleDOI

Frequent Cannabis Use Is Negatively Associated with Frequency of Injection Drug Use Among People Who Inject Drugs in a Canadian Setting

TL;DR: The findings from these prospective cohorts suggest that people who use cannabis daily were less likely to report daily injection of illegal drugs compared withPeople who use it less than daily, and the potential value of conducting experimental research to test whether controlled administration of cannabinoids impacts the frequency of illegal opioid injection among PWID.
Journal ArticleDOI

Cannabis and pain: a scoping review

TL;DR: In this paper , the authors conducted a review examining the evidence of cannabis in pain and found that it has a weak evidence for neuropathic, rheumatic, and headache, modest evidence for multiple sclerosis related pain, and as adjuvant therapy in cancer pain.
Journal ArticleDOI

Why Insurance Companies Should Pay for Medical Cannabis.

TL;DR: There are three reasons why payers should begin to cover their beneficiaries’ out-of-pocket expenses for medical cannabis, at least for those indications for which there is evidence to support its use.
References
More filters
Posted Content

Mostly Harmless Econometrics: An Empiricist's Companion

TL;DR: The core methods in today's econometric toolkit are linear regression for statistical control, instrumental variables methods for the analysis of natural experiments, and differences-in-differences methods that exploit policy changes.
Journal ArticleDOI

Adverse Health Effects of Marijuana Use

TL;DR: As marijuana use becomes legal in some states, the dominant public opinion is that marijuana is a harmless source of mood alteration, but enough information is available to cause concern.
Journal ArticleDOI

The economic costs of pain in the United States.

TL;DR: The national cost of pain ranges from $560 to $635 billion, larger than the cost of the nation's priority health conditions and the annual cost of heart disease, cancer, and diabetes.

Vital Signs: Overdoses of Prescription Opioid Pain Relievers - United States, 1999-2008

TL;DR: Wide variation among states in the nonmedical use of OPR and overdose rates cannot be explained by underlying demographic differences in state populations but is related to wide variations in OPR prescribing.
Journal ArticleDOI

Association between opioid prescribing patterns and opioid overdose-related deaths.

TL;DR: Among patients receiving opioid prescriptions for pain, higher opioid doses were associated with increased risk of opioid overdose death, and receiving both as-needed and regularly scheduled doses was not associated with overdose risk after adjustment.
Related Papers (5)